Recent studies have shown that hematopoietic stem cells (HSCs) are concentrated around the endothelium of the sinusoidal capillaries. However, the current International Commission on Radiological Protection (ICRP) dosimetry model does not take into account the heterogeneity of the bone marrow tissue and stem cell distribution. In this study, the absorbed doses to the stem cell layer in the perivascular HSC layer in the bone marrow from radionuclides inhaled into the body were estimated for the major beta- and alpha-nuclides and noble gases and compared with the absorbed dose based on the ICRP 60 and ICRP 103 recommendations. The absorbed doses to the bone marrow obtained from the model calculations were not significantly different from ICRP60 and ICRP103 for beta-nuclides but were much lower than previously estimated for alpha-nuclides, and the contribution of red bone marrow and blood sources was greater than that of trabecular bone for alpha-nuclides. Noble gases in the red bone marrow may also affect the bone marrow stem cell layer. The bone marrow dose assessment for alpha nuclides and noble gases should be re-examined using a precise model based on CT images from the perspective of occupational and public radiation protection.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes